



Saturday, February 17, 2018
UCLA Meyer & Renee Luskin Conference Center

UCLA Campus Los Angeles, California





MRI, Targeted Biopsy, Intervention and Biomarkers in Prostate Cancer Management:

A Paradigm Shift in Detection, Grading, Monitoring, Staging, Reporting, Biopsy and Treatment

General Information:

Saturday, February 17, 2018

Registration Fees:

MD Early bird (by January 28, 2018) \$275
MD (beginning January 29, 2018) \$325
Fellows/Residents/Techs \$200

Program Location:

UCLA Meyer & Renee Luskin Conference Center

425 Westwood Plaza Los Angeles, CA 90095 855-522-8252 www.luskinconferencecenter.ucla.edu

Refunds:

Cancellations must be received in writing by Friday, February 2, 2018 and will be subject to a \$50 processing fee. No refunds will be granted after the cutoff date. If, for any reason, the course must be canceled, discontinued, or rescheduled by the Office of Continuing Medical Education, a full refund will be provided.

Directions and Parking:

From the 405 freeway, exit Wilshire Blvd., East toward Westwood. Turn left on Westwood Blvd., travel past Charles E. Young Dr. South and turn left on Structure 8 driveway. Drive up the ramp to the rooftop level to park. Parking attendants will be selling permits from 6:30 AM - 8:30 AM. If you arrive outside of this time frame, please visit the parking kiosk on Westwood Plaza to pay for your parking permit. Participants are responsible for their own parking charges at a rate of \$12 per vehicle. The Luskin conference center is located at Westwood Plaza and Strathmore Place.

Additional Information:

If you have any questions, please contact the UCLA Office of Continuing Medical Education at (310) 794-2620 or visit our website at www.cme.ucla.edu.

Faculty

Course Director

Steven S. Raman, MD, FSAR, FSIR

Professor of Radiology, Urology and Surgery David Geffen School of Medicine

UCLA Faculty

Corey Arnold, PhD

Assistant Professor of Radiology and Bioengineering David Geffen School of Medicine

Albert Chang, MD, PhD

Associate Professor and Vice Chair, Surgical Services Director of Brachytherapy Services David Geffen School of Medicine

Johannes Czernin, MD

Professor of Molecular Pharmacology David Geffen School of Medicine

Ely Felker, MD

Assistant Professor of Radiology David Geffen School of Medicine

William Hsu, PhD

Associate Professor of Radiology David Geffen School of Medicine

David S. K. Lu, MD

Professor of Radiology and Surgery David Geffen School of Medicine

Leonard Marks, MD

Professor of Urology David Geffen School of Medicine

Justin McWilliams, MD

Associate Professor of Radiology David Geffen School of Medicine

Allan Pantuck, MD

Professor of Urology David Geffen School of Medicine

Matthew Rettig, MD

Professor of Oncology David Geffen School of Medicine

Robert Reiter, MD

Professor of Urology David Geffen School of Medicine

Anthony Sisk, DO

Assistant Professor of Pathology David Geffen School of Medicine

Guest Faculty

Daniel J. Margolis, MD

Associate Professor of Radiology Weill Cornell School of Medicine

PROGRAM

Saturday, February 17th

7:00	Breakfast and Registration	
8:00	Introduction to Prostate MRI	Steven S. Raman, MD, FSAR, FSIR
8:10	T2/Anatomy	Daniel J. Margolis, MD
8:25	Diffusion Weighted Imaging	Daniel J. Margolis, MD
8:40	Perfusion Imaging	Daniel J. Margolis, MD
8:55	Understanding PIRADS v2	Ely Felker, MD
9:10	Case 1: Active Surveillance and MRI	Steven S. Raman, MD, FSAR, FSIR
9:15	Active Surveillance and MRI	Leonard Marks, MD
9:30	Active Surveillance and Targeted Fusion Biopsy	Leonard Marks, MD
9:45	US Fusion Biopsy Systems: UroNAV and Koelis	Allan Pantuck, MD
10:00	MRI-Guided In-Bore Prostate Biopsy	David S. K. Lu, MD
10:15	Panel Discussion	
10:30	Morning Coffee Break	
11:00	Case 2: Surgical and Radiation Planning MRI	Steven S. Raman, MD, FSAR, FSIR
11:05	Indications for Prostate MRI	Daniel J. Margolis, MD
11:20	PSMA PET: The Best for Prostate Cancer Dx ?	Johannes Czernin, MD
11:35	Surgical Planning with Prostate MRI	Robert Reiter, MD
11:50	Prostate Pathology	Antony Sisk, DO
12:05	Radiation Therapy Planning and MRI	Albert Chang, MD, PhD
12:20	Panel Discussion	
12:35	Lunch	
1:25	Case 3: Focal Therapy: Hope or Hype ?	Ely Felker, MD
1:30	Pros of Focal Therapy	Leonard Marks, MD
1:45	Cons of Focal Therapy	Robert Reiter, MD
2:00	MR Imaging of Focal Therapy	Ely Felker, MD
2:15	Prostate Cryo, HIFU and Laser Ablation	Leonard Marks, MD
2:45	Emerging Ablative Therapies	Steven S. Raman, MD, FSAR, FSIR
3:00	Prostate Artery Embolization	Justin McWilliams, MD
3:15	Panel Discussion	
3:30	Afternoon Coffee Break	
4:00	Artificial Intelligence and Prostate MRI: The Future	Corey Arnold, PhD
4:15	Utility of Prostate Biomarkers	Robert Reiter, MD
4:30	PI-RADS v2 as an Imaging Biomarker	Daniel J. Margolis, MD
4:45	Radiogenomics and MRI: Imaging and Biology	William Hsu, PhD
5:00	Imaging as a Predictive Biomarker	Robert Reiter, MD
5:15	Understanding Advanced Prostate Cancer	Matthew Rettig, MD
5:45	Panel Discussion	
6:00	Adjourn	

Application for Enrollment (Please Print)

Course Title and Number	Registration Fee		
MRI, Targeted Biopsy, Intervention and Biomarkers in Prostate Cancer Management			
MD Early bird (by January 28, 2018)	\$275		
MD (beginning January 29, 2018)	\$325	TOTAL	
Fellows/Residents/Techs/Nurses	\$200		

Last four digits of your Social Secur	rity Number	
Name (First/Middle/Last)	☐ Male ☐ Female	
Degree	Specialty	
Preferred Mailing Address		
City/State/ZIP		
((
Area Code Phone	Area Code Fax	
Email Address		
☐ Check enclosed payable to:	Regents of the University of California	
Charge:	☐ Visa ☐ American Express	☐ Discover
Card Number		Expiration Mo/Yı
Authorizing Signature		

Enrollment:

Online — Go to www.cme.ucla.edu/courses, click on A Paradigm Shift in Detection, Grading, Monitoring, Staging, Reporting, Biopsy and Treatment, and click the registration button. You may use your MasterCard, VISA, American Express or Discover card to register online.

By Mail — Use the form attached. Mail to:
UCLA Office of Continuing Medical Education
MRI, Targeted Biopsy, Intervention and Biomarkers in Prostate Cancer Management
10920 Wilshire Blvd., Ste. 1060
Los Angeles, CA 90024-6512

By Fax — Send the completed enrollment form with credit card information and authorizing signature. FAX 310-794-2624.

By Phone — Use your MasterCard, VISA, American Express or Discover Card. Call the Office of CME at 310-794-2620.

Please visit our website for other UCLA CME offerings: www.cme.ucla.edu

Early registration is recommended as space is limited!

MRI, Targeted Biopsy, Intervention and Biomarkers in Prostate Cancer Management:

A Paradigm Shift in Detection, Grading, Monitoring, Staging, Reporting, Biopsy and Treatment

Course Description:

Prostate cancer is the second most common solid organ malignancy diagnosed in men. Unlike other solid organ malignancies, the challenge in prostate cancer is to confidently identify men with moderate and high grade cancers who would benefit most from aggressive therapy and triage the rest to active surveillance. Uniquely among solid organ cancers, imaging has not been a traditional part of the workup for prostate cancer, which has relied instead on transrectal US-guided template biopsy. Over the past few years, MR imaging has emerged as the best imaging modality to detect, grade and stage prostate cancer and is considered a valuable biomarker. The course will focus on the evolving role of MR imaging in prostate cancer diagnosis, monitoring, targeted biopsy and in focal and whole gland therapy planning. We will review all relevant MR imaging components of prostate cancer, new molecular modalities such as PSMA PET and an update on prostate cancer biomarkers.

Target Audience:

Radiologists, urologists, radiation and medical oncologists and primary care physicians interested in understanding prostate MR imaging and its applications for active surveillance, biopsy planning and acquisition, surgical planning and radiation planning and its role as a prostate biomarker

Course Objectives:

At the conclusion of this course, participants should be better able to:

- Understand state-of-the art prostate MR imaging, biomarkers and artificial intelligence
- Integrate prostate MR imaging into active surveillance and targeted biopsy planning
- Incorporate prostate MR imaging into robotic prostatectomy and radiation planning
- Illustrate the role for molecular imaging of prostate cancer: PSMA, Axumin and Choline PET
- Evaluate the risks and benefits of focal and whole gland therapies

Accreditation:

The Office of Continuing Medical Education, David Geffen School of Medicine at UCLA, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Office of Continuing Medical Education, David Geffen School of Medicine at UCLA designates this live activity for a maximum of 8 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Approved by the ASRT for Category A continuing education credit.

Disclosure Statement:

The FDA has issued a concept paper which classifies commercial support of scientific and educational programs as promotional unless it can be affirmed that the program is "truly independent" and free of commercial influence. In addition to independence, the FDA requires that non-promotional, commercially supported education be objective, balanced, and scientifically rigorous. The policy further states that all potential conflicts of interest of the CME staff and faculty be fully disclosed to the program's participants. In addition, Accreditation Council for Continuing Medical Education policy mandates that the sponsor adequately manage all identified potential conflicts of interest prior to the program. We, at UCLA, fully endorse the letter and spirit of these concepts.

ucla Health

UCLA Office of Continuing Medical Education David Geffen School of Medicine at UCLA Los Angeles, CA 90095-6938 405 Hilgard Avenue MC29

MRI, Targeted Biopsy, Intervention and Biomarkers in Prostate Cancer Management:

A Paradigm Shift in Detection, Grading, Monitoring, Staging, Reporting, Biopsy and Treatment

www.cme.ucla.edu/courses Saturday, February 17, 2018

NONPROFIT

ORGANIZATION U.S. POSTAGE

UCLA